International Journal of Cardiology Cardiovascular Risk and Prevention最新文献

英文中文

Clinical efficacy comparison between extracorporeal shock wave therapy and enhanced external counterpulsation for coronary heart disease 体外冲击波治疗与强化体外反搏治疗冠心病的临床疗效比较

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-07 DOI: 10.1016/j.ijcrp.2026.200574

Ting Zhao , Suping Lan , Yun Zhang , Yupin Dong , Lunyan Lu , Xu Chen , Song Li , Yuncheng Li , Shen Wang , Yue Wang , Xiaofan Wu , Xinjian Li

Objective

This study aims to evaluate the clinical efficacy of extracorporeal cardiac shock wave therapy(CSWT) and enhanced external counterpulsation(EECP),both individually and in combination,in patients with coronary artery disease(CAD),and to explore effective non-invasive treatment strategies.

Methods

A total of 259 patients with CAD admitted between January 2023 and June 2024 were enrolled and randomly assigned to four groups:the Control group(n = 65) received conventional medication only; the EECP group(n = 65) received conventional medication plus EECP treatment(EECP; total duration 36 h); the CSWT group(n = 64) received conventional medication plus CSWT therapy(CSWT; total duration 4.5 h); and the Combination group(EECP + CSWT group,n = 65) received conventional medication combined with both CSWT(4.5 h) and EECP(36 h).Coronary stenosis severity, cardiac function indices, blood biochemistry and other indicators were evaluated at baseline and 12 months after treatment.

Results

Baseline characteristics showed no significant differences among the groups(P > 0.05). After 12 months of treatment, the Gensini score of the EECP + CSWT group decreased by 20 points, which was significantly lower than that of the EECP group (−5 points, P < 0.05), the CSWT group (−15 points, P < 0.05) and the control group (−0.5 points, P < 0.05). Secondly, compared with the control group, the CSWT group, EECP group and EECP + CSWT group showed more significant improvements in cardiac function and blood biochemical parameters (P < 0.05). The EECP + CSWT group exhibited the most pronounced therapeutic efficacy, followed by the EECP group and the CSWT group; all three intervention groups were significantly superior to the Control group (P < 0.05).

Conclusion

Both CSWT and EECP effectively improve the severity of coronary artery disease, cardiac function,and blood biochemical parameters in CAD patients.The combination of these two therapies demonstrates synergistic effects, yielding significantly superior outcomes compared to either monotherapy.

目的评价体外心脏冲击波治疗（CSWT）和体外强化反搏（EECP）单独或联合治疗冠心病（CAD）的临床疗效，探讨有效的无创治疗策略。方法纳入2023年1月至2024年6月期间收治的CAD患者259例，随机分为4组：对照组（n = 65）仅接受常规药物治疗；EECP组（65例）给予常规药物治疗加EECP治疗（EECP，总持续时间36 h）；CSWT组（n = 64）采用常规药物加CSWT治疗（CSWT，总持续时间4.5 h）；联合组（EECP + CSWT组，n = 65）采用常规药物联合CSWT（4.5 h）和EECP（36 h）治疗。在治疗前及治疗后12个月评估冠状动脉狭窄严重程度、心功能指标、血液生化等指标。结果两组患者基线特征差异无统计学意义（P > 0.05）。治疗12个月后，EECP + CSWT组Gensini评分下降20分，显著低于EECP组（- 5分，P < 0.05）、CSWT组（- 15分，P < 0.05）和对照组（- 0.5分，P < 0.05）。其次，与对照组相比，CSWT组、EECP组和EECP + CSWT组心功能和血液生化指标改善更为显著（P < 0.05）。EECP + CSWT组治疗效果最显著，其次为EECP组和CSWT组；三个干预组均显著优于对照组（P < 0.05）。结论CSWT和EECP均能有效改善冠心病患者冠状动脉病变严重程度、心功能及血液生化指标。这两种疗法的结合显示出协同效应，与任何单一疗法相比，产生明显更好的结果。

{"title":"Clinical efficacy comparison between extracorporeal shock wave therapy and enhanced external counterpulsation for coronary heart disease","authors":"Ting Zhao , Suping Lan , Yun Zhang , Yupin Dong , Lunyan Lu , Xu Chen , Song Li , Yuncheng Li , Shen Wang , Yue Wang , Xiaofan Wu , Xinjian Li","doi":"10.1016/j.ijcrp.2026.200574","DOIUrl":"10.1016/j.ijcrp.2026.200574","url":null,"abstract":"<div><h3>Objective</h3><div>This study aims to evaluate the clinical efficacy of extracorporeal cardiac shock wave therapy(CSWT) and enhanced external counterpulsation(EECP),both individually and in combination,in patients with coronary artery disease(CAD),and to explore effective non-invasive treatment strategies.</div></div><div><h3>Methods</h3><div>A total of 259 patients with CAD admitted between January 2023 and June 2024 were enrolled and randomly assigned to four groups:the Control group(n = 65) received conventional medication only; the EECP group(n = 65) received conventional medication plus EECP treatment(EECP; total duration 36 h); the CSWT group(n = 64) received conventional medication plus CSWT therapy(CSWT; total duration 4.5 h); and the Combination group(EECP + CSWT group,n = 65) received conventional medication combined with both CSWT(4.5 h) and EECP(36 h).Coronary stenosis severity, cardiac function indices, blood biochemistry and other indicators were evaluated at baseline and 12 months after treatment.</div></div><div><h3>Results</h3><div>Baseline characteristics showed no significant differences among the groups(P > 0.05). After 12 months of treatment, the Gensini score of the EECP + CSWT group decreased by 20 points, which was significantly lower than that of the EECP group (−5 points, P < 0.05), the CSWT group (−15 points, P < 0.05) and the control group (−0.5 points, P < 0.05). Secondly, compared with the control group, the CSWT group, EECP group and EECP + CSWT group showed more significant improvements in cardiac function and blood biochemical parameters (P < 0.05). The EECP + CSWT group exhibited the most pronounced therapeutic efficacy, followed by the EECP group and the CSWT group; all three intervention groups were significantly superior to the Control group (P < 0.05).</div></div><div><h3>Conclusion</h3><div>Both CSWT and EECP effectively improve the severity of coronary artery disease, cardiac function,and blood biochemical parameters in CAD patients.The combination of these two therapies demonstrates synergistic effects, yielding significantly superior outcomes compared to either monotherapy.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200574"},"PeriodicalIF":2.1,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145976978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

“Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era” “连接后covid -19时代心肌炎的临床、分子和遗传学观点”

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-07 DOI: 10.1016/j.ijcrp.2026.200576

Siddharth Birla , Arshia Angural , Arya Madathumchalil , Ritika V. Shende , Sharvani V. Shastry , Pallavi Kanyappa Shekar , Manjappa Mahadevappa , Prashant Vishwanath , Akila Prashant

Myocarditis is a non-familial inflammatory manifestation of the myocardium, primarily induced by viral infections, but it may also stem from bacterial pathogens, autoimmune disorders, or adverse drug reactions. Its diagnosis remains challenging due to heterogeneous and often non-specific clinical presentations. Recent epidemiological studies have indicated a markedly increased incidence of myocarditis following SARS-CoV-2 infection and mRNA COVID-19 vaccinations (to a lesser extent) compared to pre-pandemic statistics. While a significant number of cases follow a mild and self-limiting disease course, severe manifestations can lead to arrhythmias, heart failure, or even sudden cardiac death. Importantly, accumulating evidence indicates that even mild myocarditis confers an elevated long-term risk of adverse cardiovascular outcomes. Beyond clinical and imaging-based observations, recent advances highlight a critical role for host genetic susceptibility in modulating immune responses, myocardial injury, and disease severity. This review provides a comprehensive synthesis of the etiology, pathophysiological mechanisms, clinical spectrum, diagnostic approaches, and evidence-based management of COVID-19-associated myocarditis, while critically integrating emerging genetic and transcriptomic insights that may explain disease heterogeneity, variable inter-individual susceptibility, and long-term prognosis. By bridging clinical aspects with molecular and genetic frameworks, this review underscores the importance of personalized risk stratification, vigilant post-recovery surveillance, and targeted preventive strategies in the post-pandemic era.

心肌炎是心肌的一种非家族性炎症表现，主要由病毒感染引起，但也可能源于细菌病原体、自身免疫性疾病或药物不良反应。由于异质性和非特异性的临床表现，其诊断仍然具有挑战性。最近的流行病学研究表明，与大流行前的统计数据相比，SARS-CoV-2感染和mRNA - COVID-19疫苗接种后心肌炎的发病率（在较小程度上）显着增加。虽然相当数量的病例遵循轻微和自限性的病程，但严重的表现可导致心律失常，心力衰竭，甚至心源性猝死。重要的是，越来越多的证据表明，即使是轻微的心肌炎也会增加不良心血管结局的长期风险。除了临床和基于成像的观察，最近的进展强调了宿主遗传易感性在调节免疫反应、心肌损伤和疾病严重程度方面的关键作用。本综述全面综合了covid -19相关心肌炎的病因学、病理生理机制、临床谱、诊断方法和循证管理，同时批判性地整合了新出现的遗传和转录组学见解，这些见解可能解释疾病异质性、可变个体间易感性和长期预后。通过将临床方面与分子和遗传框架联系起来，本综述强调了在大流行后时代个性化风险分层、警惕的康复后监测和有针对性的预防策略的重要性。

{"title":"“Bridging the clinical, molecular and genetic perspectives on myocarditis in post-COVID-19 era”","authors":"Siddharth Birla , Arshia Angural , Arya Madathumchalil , Ritika V. Shende , Sharvani V. Shastry , Pallavi Kanyappa Shekar , Manjappa Mahadevappa , Prashant Vishwanath , Akila Prashant","doi":"10.1016/j.ijcrp.2026.200576","DOIUrl":"10.1016/j.ijcrp.2026.200576","url":null,"abstract":"<div><div>Myocarditis is a non-familial inflammatory manifestation of the myocardium, primarily induced by viral infections, but it may also stem from bacterial pathogens, autoimmune disorders, or adverse drug reactions. Its diagnosis remains challenging due to heterogeneous and often non-specific clinical presentations. Recent epidemiological studies have indicated a markedly increased incidence of myocarditis following SARS-CoV-2 infection and mRNA COVID-19 vaccinations (to a lesser extent) compared to pre-pandemic statistics. While a significant number of cases follow a mild and self-limiting disease course, severe manifestations can lead to arrhythmias, heart failure, or even sudden cardiac death. Importantly, accumulating evidence indicates that even mild myocarditis confers an elevated long-term risk of adverse cardiovascular outcomes. Beyond clinical and imaging-based observations, recent advances highlight a critical role for host genetic susceptibility in modulating immune responses, myocardial injury, and disease severity. This review provides a comprehensive synthesis of the etiology, pathophysiological mechanisms, clinical spectrum, diagnostic approaches, and evidence-based management of COVID-19-associated myocarditis, while critically integrating emerging genetic and transcriptomic insights that may explain disease heterogeneity, variable inter-individual susceptibility, and long-term prognosis. By bridging clinical aspects with molecular and genetic frameworks, this review underscores the importance of personalized risk stratification, vigilant post-recovery surveillance, and targeted preventive strategies in the post-pandemic era.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200576"},"PeriodicalIF":2.1,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146022630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prognostic value of jugular, pulmonary and inferior vena cava ultrasound in decompensated heart failure in primary care 颈静脉、肺静脉和下腔静脉超声在初级保健失代偿性心力衰竭中的预后价值

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-05 DOI: 10.1016/j.ijcrp.2026.200571

Victoria Cendrós , Elena Navas , Esther Miranzo , Miguel Ángel Muñoz , Laura Pirretas , Leila Pifarrè , Marco Inzoli , Cristina Enjuanes , Verónica Sierra , Ana Roger , Rosa Caballol-Angelats , José María Verdú-Rotellar

Background

Multiparametric ultrasound combining pulmonary and venous assessment (inferior vena cava [IVC] and internal jugular vein) is a feasible tool for characterizing hemodynamic congestion in patients with heart failure (HF) managed in Primary Care.

Objective

To evaluate the short-term prognostic value of pulmonary and venous ultrasound in patients with decompensated HF treated with intravenous diuretics in community settings.

Methods

Prospective cohort study including patients with decompensated HF attended between April 2024 and September 2025 across seven Primary Care teams of the Catalan Health Institute. Clinical, analytical, and ultrasound variables (IVC, jugular vein, and 8-zone lung ultrasound) were recorded. The primary outcome was a composite of death, HF hospitalisation, or new intravenous treatment within seven days.

Results

A total of 197 patients were included (56.4 % women; mean age 84.7 ± 7.5 years). Signs of venous and pulmonary congestion were frequent at inclusion. Within seven days, 14.8 % of patients experienced the composite outcome. In multivariate analysis, IVC collapsibility <25 % (OR 3.70; 95 % CI 1.13–14.53; p = 0.039) and prior heart failure hospitalisation (OR 4.47; 95 % CI 1.48–14.10; p = 0.008) were independently associated with events, whereas lung and jugular ultrasound parameters were not.

Conclusions

Multiparametric ultrasound performed in Primary Care allows identification and quantification of hemodynamic congestion in decompensated HF. Among evaluated parameters, only IVC collapsibility showed independent short-term prognostic value, supporting its integration into community-based risk stratification models.

多参数超声联合肺和静脉评估（下腔静脉[IVC]和颈内静脉）是一种可行的工具，用于表征心力衰竭（HF）患者的血流动力学充血。目的评价肺静脉超声对社区内静脉利尿剂治疗失代偿期心衰患者的短期预后价值。方法前瞻性队列研究，纳入2024年4月至2025年9月在加泰罗尼亚卫生研究所7个初级保健团队就诊的失代偿性心衰患者。记录临床、分析和超声变量（IVC、颈静脉和8区肺超声）。主要结局是7天内死亡、HF住院或新的静脉注射治疗的综合结果。结果共纳入197例患者，其中女性56.4%，平均年龄84.7±7.5岁。静脉和肺部充血的迹象是常见的纳入。在7天内，14.8%的患者出现了复合结果。在多变量分析中，下腔静脉溃散性<； 25% （OR 3.70; 95% CI 1.13-14.53; p = 0.039）和既往心力衰竭住院（OR 4.47; 95% CI 1.48-14.10; p = 0.008）与事件独立相关，而肺和颈静脉超声参数与事件无关。结论在初级保健中应用多参数超声可识别和量化失代偿性心衰的血流动力学充血。在评估的参数中，只有IVC溃散性具有独立的短期预后价值，支持将其纳入社区风险分层模型。

{"title":"Prognostic value of jugular, pulmonary and inferior vena cava ultrasound in decompensated heart failure in primary care","authors":"Victoria Cendrós , Elena Navas , Esther Miranzo , Miguel Ángel Muñoz , Laura Pirretas , Leila Pifarrè , Marco Inzoli , Cristina Enjuanes , Verónica Sierra , Ana Roger , Rosa Caballol-Angelats , José María Verdú-Rotellar","doi":"10.1016/j.ijcrp.2026.200571","DOIUrl":"10.1016/j.ijcrp.2026.200571","url":null,"abstract":"<div><h3>Background</h3><div>Multiparametric ultrasound combining pulmonary and venous assessment (inferior vena cava [IVC] and internal jugular vein) is a feasible tool for characterizing hemodynamic congestion in patients with heart failure (HF) managed in Primary Care.</div></div><div><h3>Objective</h3><div>To evaluate the short-term prognostic value of pulmonary and venous ultrasound in patients with decompensated HF treated with intravenous diuretics in community settings.</div></div><div><h3>Methods</h3><div>Prospective cohort study including patients with decompensated HF attended between April 2024 and September 2025 across seven Primary Care teams of the Catalan Health Institute. Clinical, analytical, and ultrasound variables (IVC, jugular vein, and 8-zone lung ultrasound) were recorded. The primary outcome was a composite of death, HF hospitalisation, or new intravenous treatment within seven days.</div></div><div><h3>Results</h3><div>A total of 197 patients were included (56.4 % women; mean age 84.7 ± 7.5 years). Signs of venous and pulmonary congestion were frequent at inclusion. Within seven days, 14.8 % of patients experienced the composite outcome. In multivariate analysis, IVC collapsibility <25 % (OR 3.70; 95 % CI 1.13–14.53; p = 0.039) and prior heart failure hospitalisation (OR 4.47; 95 % CI 1.48–14.10; p = 0.008) were independently associated with events, whereas lung and jugular ultrasound parameters were not.</div></div><div><h3>Conclusions</h3><div>Multiparametric ultrasound performed in Primary Care allows identification and quantification of hemodynamic congestion in decompensated HF. Among evaluated parameters, only IVC collapsibility showed independent short-term prognostic value, supporting its integration into community-based risk stratification models.</div></div>","PeriodicalId":29726,"journal":{"name":"International Journal of Cardiology Cardiovascular Risk and Prevention","volume":"28 ","pages":"Article 200571"},"PeriodicalIF":2.1,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-01

引用次数: 0

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-01

引用次数: 0

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-01

引用次数: 0

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-01

引用次数: 0

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-01

引用次数: 0

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-01

引用次数: 0

IF 2.1 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Cardiology Cardiovascular Risk and Prevention

Pub Date : 2026-01-01

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

International Journal of Cardiology Cardiovascular Risk and Prevention

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀